Open Access Full Text Article

CORRIGENDUM

Synergistic Effect Of A Retinoid X Receptor-Selective Ligand Bexarotene And Docetaxel In Prostate Cancer [Corrigendum]

Shen D, Wang H, Zheng Q, et al. Onco Targets Ther. 2019;12:7877–7886.

The authors apologize for this error.

Upon reviewing the article, the authors noticed an error in two of the authors name (page 7877). The correct author names are Liqun Xia and Gonghui Li.

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal



OncoTargets and Therapy 2019:12 8807

8807

© 2019 Shen et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License.(http://creativecommons.org/licenses/by-mc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 42 and 5 d our Terms (https://www.dovepress.com/terms.php).